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O B J E C T I V E S To test the hypothesis that carriers of Dutch founder mutations in cardiac myosin-
binding protein C (MYBPC3), without left ventricular hypertrophy (LVH) or electrocardiographic
abnormalities, have diastolic dysfunction on tissue Doppler imaging (TDI), which can be used for the
screening of family members in the hypertrophic cardiomyopathy (HCM) population.
B A C KG ROUND TDI is a more sensitive technique for the assessment of left ventricular contraction
and relaxation abnormalities than is conventional echocardiography.
METHOD S Echocardiographic studies including TDI were performed in genotyped hypertrophic
cardiomyopathy patients (genotype-positive, G/LVH; n  27), mutation carriers without LVH
(G/LVH; n 27), and healthy controls (n 55). The identiﬁed mutations in MYBPC3 in the G/LVH
subjects were c.2864_2865delCT (12 subjects), c.2373dupG (n  8), and p. Arg943X (n  7). In the
G/LVH subjects, the following mutations were identiﬁed: c.2864_2865delCT (n  11), c.2373dupG
(n  8), and p. Arg943X (n  8).
R E S U L T S Mean TDI-derived systolic and early and late diastolic mitral annular velocities were
signiﬁcantly lower in the G/LVH subjects compared with the other groups. However, there was no
difference between controls and G/LVH subjects. Mean TDI-derived late mitral annular diastolic
velocities were signiﬁcantly higher in the G/LVH subjects compared with controls and G/LVH
subjects. Using a cut-off value of mean  2 SD, an abnormal late mitral annular diastolic velocity was
found in 14 (51%) of G/LVH patients. There was no difference among the 3 different mutations.
CONC L U S I O N S In contrast to earlier reports, mean mitral annular systolic velocity and early mitral
annular diastolic velocity velocities were not reduced in G/LVH subjects, and TDI velocities were not
sufﬁciently sensitive for determination of the affected status of an individual subject. Our ﬁndings,
however, support the theory that diastolic dysfunction is a primary component of pre-clinical
HCM. (J Am Coll Cardiol Img 2009;2:58–64) © 2009 by the American College of Cardiology Foundation
From the Departments of *Cardiology and †Clinical Genetics, Thoraxcenter, Erasmus University Medical Center Rotterdam,
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59ypertrophic cardiomyopathy (HCM) is de-
fined by the presence of left ventricular
hypertrophy (LVH) in the absence of load-
ing conditions (hypertension, valve disease)
ufficient to cause the observed abnormality (1). In
ost cases, it is a familial disease with an autosomal
ominant pattern of inheritance caused by muta-
ions in genes that encode different proteins of the
ardiac sarcomere. However, LVH is absent in a
ignificant number of mutation carriers because of
he variable penetrance of the mutations and con-
ounding effects of modifier genes, sex, and envi-
onmental factors. Overall, LVH is neither very
ensitive nor very specific in HCM diagnosis (2–4).
See page 65
An alternative approach to the early diagnosis of
CM is genetic testing, which can identify mutation
arriers before development of LVH. However, using
he current techniques, sarcomeric mutations are iden-
ified in 50% to 60% of HCM patients, making
creening of family members by genetic testing im-
ossible in up to 50% of HCM families (5).
Experimental data suggest that cardiac myocyte
ontractile function in HCM is reduced and that
he hypertrophy is compensatory (6,7). These data,
n conjunction with myocyte disarray, the charac-
eristic hallmark of HCM, led to the hypothesis
hat tissue Doppler imaging (TDI), with its possi-
ility to identify contraction and relaxation abnor-
alities, would be more sensitive for the diagnosis
f HCM than conventional echocardiography. This
rinciple has been proven by several studies in both
nimals and patients carrying different sarcomeric
utations (8–10).
The current study was performed to test the
ypothesis that TDI can be used for the screening
f family members in the Dutch HCM population.
he Dutch HCM population is special because the
ajority of HCM in the Netherlands is caused by 1
f 3 founder mutations in cardiac myosin-binding
rotein C (MYBPC3); c.2373dupG (11),
.2864_2865delCT, and p. Arg943X.
ETHODS
tudy population. At our cardiogenetic outpatient
linic, systematic family screenings of genotyped
CM patients are performed. The mutation carri-
rs (G/LVH–; n  27) were selected from
onsecutive genotyped family members without
ajor or minor criteria for the diagnosis of HCM Tn routine echocardiography or electrocardiography
s described by McKenna et al. (12). The control
roup consisted of 55 healthy age- and gender-
atched subjects without cardiovascular disease or
iabetes mellitus and with normal left atrial dimen-
ion and left ventricular dimension and function.
he third group included 27 HCM patients (LV
all thickness 15 mm) based on 1 of the Dutch
ounder mutations. All subjects provided informed
ritten consent. The study complies with the Dec-
aration of Helsinki, and the Erasmus University
edical Center Review Board has approved the
tudy.
-dimensional echocardiography. Echocardiographic
tudies were performed with a Sonos 7500 ultra-
ound system with a S3 transducer or an iE33
ystem with a S5-1 transducer (Philips Medical
ystems, Best, the Netherlands). The ac-
uired data were digitally stored and sub-
equently analyzed by an observer, who
as blinded to the clinical data. From the
econd harmonic M-mode recordings, the
ollowing data were acquired: left atrial
imension, left ventricular septal and pos-
erior wall thickness, and left ventricular
nd-diastolic and end-systolic dimension.
rom the Doppler mitral-inflow pattern,
arly (E) and late (A) left ventricular filling
elocities, the E/A ratio, E-velocity decel-
ration time, and the duration of the A
ere measured. Pulmonary vein systolic
ow, diastolic flow, and flow during atrial
ontraction were also measured. Left ven-
ricular ejection fraction was assessed on
-dimensional echocardiography using the
iplane Simpson method.
DI. TDI was performed by placing the
ample volume at the side of the medial, lateral,
nferior, anterior, posterior, and anteroseptal mitral
nnulus in the standard apical views. Gain and filter
ettings were adjusted as needed to eliminate back-
round noise and to allow for a clear tissue signal.
o acquire the highest tissue velocities, the angle
etween the Doppler beam and the longitudinal
otion of the investigated structure was adjusted to
minimal level. The mitral annular systolic (Sa)
nd early (Ea) and late (Aa) diastolic velocities were
ecorded at end-expiratory at a sweep speed of 100
m/s and measured using electronic calipers with
nconcert software (Philips Medical Systems).
DI-derived Sa, Ea, and Aa mitral annular veloc-
ties from 6 mitral annular regions were measured.
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60sed for analysis. The different mitral annular re-
ions were also compared. The dimensionless ratio
f E/Ea was computed at all corners; this parameter
s an index that corrects for the influence of left
entricular relaxation on mitral peak E velocity and
rovides a good estimate of left ventricular filling
ressures in HCM (13).
Diastolic function was subsequently graded 0 to
, as previously described (14). Based on color
oppler and TDI measurements, normal left ven-
ricular diastolic function (stage 0) was defined as a
ombination of E/A ratio between 0.75 and 1.50,
eceleration time between 150 and 220 ms, pulmo-
ary vein systolic flow greater than diastolic flow,
uration of the pulmonary vein flow during atrial
ontraction less than A-wave duration 30 ms,
ean Ea 10.0 cm/s, and E/Ea 9. Stage 1
Table 1. Subject Characteristics
Characteristics
G/LVH
(n  27)
G/LVH
(n  27)
Controls
(n  55)
Age, yrs 47 12*† 37 12 37 10
Percentage male 63*† 33 37
Identiﬁed mutation
2864delCT 12 11 0
2373insG 8 8 0
R943X 7 8 0
Between-groups Games-Howell–corrected p value: *p  0.01 versus controls;
†p  0.01 versus G/LVH subjects.
G  genotype; LVH  left ventricular hypertrophy.
raphic Characteristics of the Study Population
G/LVH Subjects
(n  27)
G/LVH Subjects
(n  27)
Controls
(n  55)
46 6 49 5 50 5
28 8 30 5 31 5
39 9 38 7 36 7
61 11 61 5 62 7
19 5*† 10 2 9 1
11 2 9 2 9 2
49 9*† 36 5 32 5
5 27 55
5 0 0
7 0 0
7 0 0
3 0 0
well-corrected p value: *p  0.01 versus controls; †p  0.01 versus G/LVH
ng; G  genotype; IVS  interventricular septal thickness; LA  left atrial
ntricular end-diastolic diameter; LVESD  left ventriclar end-systolic diameter;
ertrophy; LVPW  left ventricular posterior wall thickness; stages of diastolic
ormal, stage 1  abnormal relaxation, stage 2  pseudonormal, stage 3 gtage 4  ﬁxed restrictive.iastolic dysfunction (impaired LV relaxation) was
efined as an E/A ratio 0.75 and deceleration
ime 220 ms. Stage 2 diastolic dysfunction
pseudonormal LV filling) was defined as an E/A
atio between 0.75 and 1.5, with a mean Ea 7
m/s and E/Ea 15. Stage 3 diastolic dysfunction
reversible restrictive LV filling) was defined as an
/A ratio 1.5 with a deceleration time 150 ms,
ean Ea 7 cm/s, and E/Ea 15 reversing to
seudonormal or even impaired relaxation during
he Valsalva maneuver. Stage 4 diastolic dysfunc-
ion (fixed restrictive) was defined as E/A ratio
1.5 with a deceleration time150 ms, a mean Ea
7 cm/s, and an E/Ea 15 without change with
alsalva (14–16).
tatistical analyses. All statistics were performed
sing the SPSS version 14 for Windows (SPSS
nc., Chicago, Illinois). Descriptive data were com-
uted as a mean value  SD. Variables among the
groups were compared by analysis of variance
sing the Games-Howell corrections for post-hoc
nalysis. Statistical significance was defined by p 
.05. The Welch and Brown-Forsyth test con-
rmed the standard statistics.
E SULTS
tudy population. The subject characteristics are
isplayed in Table 1. The mean age and the sex of
ontrols and G/LVH subjects were similar. In
he G/LVH population, the mean age was
ignificantly higher, and there were significantly
ore males compared with the other 2 groups.
mong the G/LVH subjects, the distribution
f the MYBPC3 mutations was as follows:
.2864_2865delCT in 11, c.2373dupG in 8, and
.Arg943X in 8 subjects. Among the G/LVH
ubjects, the distribution of the MYBPC3 muta-
ions was as follows: c.2864_2865delCT in 12,
.2373dupG in 8, and p.Arg943X in 7 subjects.
chocardiographic analysis. All subjects had
-dimensional and Doppler studies satisfactory for
nalysis. The results of the echocardiographic anal-
sis are displayed in Table 2.
By definition, mean septal wall thickness was
ignificantly higher in the G/LVH subjects
ompared with the control group and the G/
VH subjects. There were no differences in left
entricular end-diastolic diameter, left ventricular
nd-systolic diameter, fractional shortening, and
eft ventricular ejection fraction among the 3Table 2. Echocardiog
2D echocardiography
LVEDD (mm)
LVESD (mm)
FS (%)
EF (%)
IVS (mm)
LVPW (mm)
LA (mm)
Diastolic dysfunction
Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
Between groups Games-Ho
subjects.
FS  fractional shorteni
diameter; LVEDD  left ve
LVH  left ventricular hyp
dysfunction, stage 0  nroups. Left atrial dimension was significantly
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61igher in the G/LVH subjects compared with
he other 2 groups.
All patients with definite HCM were in sinus
hythm. None had a left ventricular outflow tract
radient 50 mm Hg. Most patients, 16 (60%),
ere asymptomatic; 11 (40%) were in New York
eart Association functional class II. Medical
reatment was used by 12 (44%) of the HCM
atients, and consisted of beta-blockers for 6 (22%)
atients, a combination of a beta-blocker and di-
retics for 2 (7%) patients, and a combination of a
eta-blocker, diuretics, and angiotensin-converting
nzyme inhibitors for 3 (11%) patients; amiodarone
as used by 1 (4%) HCM patient.
Diastolic function was normal (grade 0) in all
ontrols and all G/LVH subjects. In the ma-
ority of G/LVH subjects, diastolic dysfunction
as present.
Mean Sa, Ea, and Aa velocities were significantly
ower in the G/LVH subjects compared with
ontrols and G/LVH subjects. Mean Sa and Ea
ere no different between controls and G/LVH
ubjects. However, mean Aa velocities were signif-
cantly higher in the G/LVH subjects com-
ared with controls and G/LVH subjects (Fig.
). Using a cut-off value of mean  2SD (97
m/s), an abnormal Aa was found in 14 (51%) of
/LVH patients. The G/LVH patients
ave abnormal regional velocities compared with
/LVH subjects and controls (Fig. 2). In the
/LVH patients, Aa velocity was abnormal in
ost of the mitral annular regions. There was no
ifference among the 3 different mutations.
I SCUS S ION
ypertrophic cardiomyopathy is a primary disorder
f cardiac myocytes, characterized by hypertrophy
n the absence of increased external load. In most
ases, it is an autosomal-dominant disease, and
outine echocardiography and electrocardiography
re used to screen family members (12). However,
VH is absent in a significant number of mutation
arriers. Early and accurate phenotypic diagnosis of
ffected family members by TDI could provide an
pportunity to prevent or modify the clinical man-
festations of HCM and would complement genetic
esting, which is complicated by allelic and nonal-
elic heterogeneity. In contrast to earlier reports, in
ur study population, mean Sa and mean Ea veloc-
ties were not reduced in G/LVH subjects
ompared with controls and could not be used to
ifferentiate the G/LVH subjects from theFigure 1. Individual Mean Values of Tissue Doppler Velocity
The individual mean values of the peak early systolic (A), peak
early diastolic (B), and peak late diastolic (C) components of
longitudinal velocity obtained from tissue Doppler imaging,
which are averaged from 6 different mitral annular sites (ante-
rior, anteroseptal, inferior, lateral, posterior, and posteroseptal)
in the hypertrophic cardiomyopathy (HCM) patients, family
members, and healthy controls. Aa  late mitral annular dia-
stolic velocity; Ea  early mitral annular diastolic velocity;
G/LVH  genotyped hypertrophic cardiomyopathy
patients; G/LVH  carriers of Dutch myosin-binding pro-
tein C founder mutations without left ventricular hypertrophy;
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62ontrols. The reasons for this difference could be
he underlying sarcomeric mutation. Unlike previ-
us studies, our study population consisted only of
ubjects with a truncating mutation in MYBPC3,
hich is known for its later onset of HCM com-
ared with mutations in the beta-myosin heavy
hain (2).
We did, however, find an increased Aa velocity in
he majority of G/LVH subjects carrying 1 of 3
runcating Dutch founder mutations in MYBPC3.
o our knowledge, this is the first study to describe
n isolated increase in mean Aa velocity in G/
VH subjects. An increase of mean Aa velocity
eans that the mitral annulus displacement is
ncreased during late diastole. This could be a very
arly sign of diastolic abnormality, preceding other
igns of myocardial contraction and relaxation ab-
ormalities and LVH (1).
Prediction of genetic abnormalities in patients
ith a clinical diagnosis of HCM and vice versa has
een investigated in several studies (17–19). Fifty
ercent to 60% of HCM patients have abnormali-
ies in the sarcomeric genes (20). Most HCM
utations are found in the beta-myosin heavy
hain, which encodes a thick myofilament protein,
nd in MYBPC3, which encodes an intermediate
yofilament protein. Mutations in both genes
ause an indistinguishable disease phenotype in
hich the ventricular septum has a characteristic
everse curve in approximately 40% of cases (20).
ne of the great benefits of genetic analyses in
CM families is the identification of at-risk family
embers, which will allow early detection and
ossible prevention of poor outcome (21).
In the present study, almost all MYBPC3 muta-
ion carriers have an increased left ventricular late
iastolic lengthening in the form of high Aa peak
elocity on TDI. In contrast to HCM mutations in
ther sarcomeric genes, which are mostly missense
utations, most MYBPC3 mutations are truncat-
ng mutations. Haplo insufficiency is, therefore,
hought to be an important disease mechanism in
YBPC3-associated HCM. The 3 described mu-
ations in this study are truncating mutations,
hought to lead to a reduction in MYBPC3 protein
ecause of a lack of expression from the mutated
llele by the cellular surveillance mechanism of
onsense-mediated decay (22). The regulatory role
f MYBPC3 on contraction is still controversial;
lthough it has been shown that removal of the
YBPC3 can increase the velocity of shortening,
orce output, and force redevelopment in skinnedFigure 2. Mean Regional Values of Tissue Doppler Velocity
Mean regional values of the 3 components of tissue Doppler longitudinal
velocity from 6 mitral annular sites during systole (A), early diastole (B), and
late diastole (C) in genotyped hypertrophic cardiomyopathy patients (G/
LVH), mutation carriers without left ventricular hypertrophy (G/LVH),
and controls. Mitral annular regions in sequence are as follows: PS  pos-
teroseptal; LAT  lateral; INF  inferior; ANT  anterior; POS  posterior;
and AS  anteroseptal. Between-groups Games-Howell–corrected p value:
all G/LVH mean values of mitral annular systolic velocity (Sa), early mitral
annular diastolic velocity (Ea), and late mitral annular diastolic velocity (Aa),
averaged from 6 mitral annular sites and individual sites, are signiﬁcantly
different from other 2 groups (p  0.001). Between mutation carriers and
controls: *p  0.01 mutation carriers versus controls; †p  0.05 mutation
carriers versus controls. Within-group Games-Howell–corrected p value:
‡p  0.01 versus the other 5 segments; §p  0.05 versus lateral and poste-
rior segments; ¶p  0.05 versus posteroseptal, lateral, inferior, and anterior
segments; and #p  0.05 versus lateral, inferior, anterior, and posteriorreparation (23–26).
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63Pohlmann et al. (27) investigated the conse-
uences of removal of MYBPC3 in ventricular
yocytes and left atria from MYBPC3 knockout
ice compared with wild type. Both sarcomere
hortening and Ca2 transient were prolonged in
YBPC3 knockout mice. Isolated left atria of
YBPC3 knockout mice exhibited a marked in-
rease in sensitivity to external Ca2 and low
icromolar Ca2. The main consequence of re-
oval of MYBPC3 in the MYBPC3 knockout
ice was a defect in diastolic relaxation and a
maller dynamic range of cell shortening, both of
hich likely result from the increased myofilament
a2 sensitivity (27). Therefore, MYBPC3 might
unction as a restraint on myosin-actin interaction
t low Ca2 and short sarcomere length to allow8. Nagueh SF, Kopelen HA, Lim DS, et
al. Tissue Doppler imaging consis-
TE. A practical app
cardiographic evaluhese experimental findings to our findings, the late
iastolic abnormality can be a very early sign or
re-clinical phenotypic expression of disease in the
/LVH subjects.
ONCLUS IONS
ased on the current study, we conclude that TDI
elocities are not sufficiently sensitive for determi-
ation of affected status of an individual patient.
ur findings, however, support the theory that
iastolic dysfunction is a primary component of
re-clinical HCM.
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